SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery

Key Points The genetic cause of SCID impacts on survival and immune reconstitution and should be considered in tailoring HCT for individual patients. Total and naive CD4+ cell counts in SCID patients 6 and 12 months post-HCT predict long-term survival and sustained immune reconstitution.

Download Full-text

Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 × 106/l

AIDS ◽

10.1097/00002030-199502000-00005 ◽

1995 ◽

Vol 9 (2) ◽

pp. 145-152

Author(s):

Donald R. Hoover ◽

Charles Rinaldo ◽

Yanhua He ◽

John Phair ◽

John Fahey ◽

...

Keyword(s):

Term Survival ◽

Long Term Survival ◽

Cell Counts ◽

Cd4 Cell Counts ◽

Cd4 Cell

Download Full-text

Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 × 106/l

AIDS ◽

10.1097/00002030-199509020-00005 ◽

1995 ◽

Vol 9 (2) ◽

pp. 145-152 ◽

Cited By ~ 20

Author(s):

Donald R. Hoover ◽

Charles Rinaldo ◽

Yanhua He ◽

John Phair ◽

John Fahey ◽

...

Keyword(s):

Term Survival ◽

Long Term Survival ◽

Cell Counts ◽

Cd4 Cell Counts ◽

Cd4 Cell

Download Full-text

Causes and outcomes of hospitalizations among people living with HIV in Georgia’s referral institution, 2012–2017

International Journal of STD & AIDS ◽

10.1177/0956462420984701 ◽

2021 ◽

Vol 32 (7) ◽

pp. 662-670

Author(s):

Nino Rukhadze ◽

Ole Kirk ◽

Nikoloz Chkhartishvili ◽

Natalia Bolokadze ◽

Lali Sharvadze ◽

...

Keyword(s):

Multivariate Analysis ◽

Clinical Immunology ◽

Fatal Outcome ◽

Cd4 Count ◽

People Living With Hiv ◽

Lethal Outcome ◽

Cell Counts ◽

Cd4 Cell Counts ◽

Living With Hiv ◽

Cd4 Cell

We assessed trends in causes and outcomes of hospitalization among people living with HIV (PLWH) admitted to the Infectious Diseases, AIDS and Clinical Immunology Research Center (IDACIRC) in Tbilisi, Georgia. Retrospective analysis included adult PLWH admitted to IDACIRC for at least 24 h. Internationally validated categorization was used to split AIDS admissions into mild, moderate, and severe AIDS. A total of 2085 hospitalizations among 1123 PLWH were registered over 2012–2017 with 65.1% (731/1123) of patients presenting with CD4 count <200. Of 2085 hospitalizations, 931 (44.7%) were due to AIDS-defining illnesses. In 2012, AIDS conditions accounted for 50.3% of admissions compared to 41.6% in 2017 ( p = 0.16). Overall, 167 hospitalizations (8.0%) resulted in lethal outcome. AIDS admissions had higher mortality than non-AIDS admissions (11.5% vs 5.2%, p < 0.0001). Among 167 deceased patients, 137 (82.0%) had CD4 count <200 at admission. In multivariate analysis, factors significantly associated with mortality included severe AIDS versus non-AIDS admission (OR 2.81, 95% CI: 1.10–7.15), CD4 cell counts <50 (OR 4.34, 95% CI: 2.52–7.47), and 50–100 (OR 2.37, 95% CI: 1.27–4.42) versus >200. Active AIDS disease remains a significant cause of hospitalization and fatal outcome in Georgia. Earlier diagnosis of HIV is critical for decreasing AIDS hospitalizations and mortality.

Download Full-text

CD4 Cell Counts at HIV Diagnosis among HIV Outpatient Study Participants, 2000–2009

AIDS Research and Treatment ◽

10.1155/2012/869841 ◽

2012 ◽

Vol 2012 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Kate Buchacz ◽

Carl Armon ◽

Frank J. Palella ◽

Rose K. Baker ◽

Ellen Tedaldi ◽

...

Keyword(s):

Hiv Testing ◽

Population Level ◽

Cd4 Count ◽

Hiv Diagnosis ◽

Cell Counts ◽

Late Hiv Diagnosis ◽

Cd4 Cell Counts ◽

The Usa ◽

Study Participants ◽

Cd4 Cell

Background. It is unclear if CD4 cell counts at HIV diagnosis have improved over a 10-year period of expanded HIV testing in the USA.Methods. We studied HOPS participants diagnosed with HIV infection ≤6 months prior to entry into care during 2000–2009. We assessed the correlates of CD4 count <200 cells/mm3at HIV diagnosis (late HIV diagnosis) by logistic regression.Results. Of 1,203 eligible patients, 936 (78%) had a CD4 count within 3 months after HIV diagnosis. Median CD4 count at HIV diagnosis was 299 cells/mm3and did not significantly improve over time (P=0.13). Comparing periods 2000-2001 versus 2008-2009, respectively, 39% and 35% of patients had a late HIV diagnosis (P=0.34). Independent correlates of late HIV diagnosis were having an HIV risk other than being MSM, age ≥35 years at diagnosis, and being of nonwhite race/ethnicity.Conclusions. There is need for routine universal HIV testing to reduce the frequency of late HIV diagnosis and increase opportunity for patient- and potentially population-level benefits associated with early antiretroviral treatment.

Download Full-text

Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial

The Lancet Global Health ◽

10.1016/s2214-109x(17)30372-8 ◽

2017 ◽

Vol 5 (11) ◽

pp. e1080-e1089 ◽

Cited By ~ 62

Author(s):

Anani Badje ◽

Raoul Moh ◽

Delphine Gabillard ◽

Calixte Guéhi ◽

Mathieu Kabran ◽

...

Keyword(s):

Preventive Therapy ◽

West African ◽

Isoniazid Preventive Therapy ◽

Risk Of Death ◽

Cell Counts ◽

Cd4 Cell Counts ◽

Long Term Follow Up ◽

Cd4 Cell

Download Full-text

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Blood Advances ◽

10.1182/bloodadvances.2019000468 ◽

2019 ◽

Vol 3 (22) ◽

pp. 3740-3749 ◽

Cited By ~ 1

Author(s):

Tsila Zuckerman ◽

Ron Ram ◽

Luiza Akria ◽

Maya Koren-Michowitz ◽

Ron Hoffman ◽

...

Keyword(s):

Older Adults ◽

Acute Leukemia ◽

Phase 1 ◽

Intensive Therapy ◽

High Dose ◽

Term Survival ◽

Long Term Survival ◽

Key Points ◽

High Dose Cytarabine

Key Points The majority of older adults or unfit acute leukemia patients are not offered intensive therapy, resulting in dismal long-term survival. A novel cytarabine prodrug BST-236 enables delivery of high-dose cytarabine and appears to be safe and efficacious in these patients.

Download Full-text

Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Related Mortality

Open Forum Infectious Diseases ◽

10.1093/ofid/ofx162.139 ◽

2017 ◽

Vol 4 (suppl_1) ◽

pp. S59-S59

Author(s):

Mark Kristoffer Pasayan ◽

Mary Lorraine Mationg ◽

David Boettiger ◽

Wilson Lam ◽

Fujie Zhang ◽

...

Keyword(s):

Sensitivity Analyses ◽

Immune Recovery ◽

Combination Antiretroviral Therapy ◽

Cd4 Counts ◽

Art Initiation ◽

Cell Counts ◽

Cd4 Cell Counts ◽

Cd4 Cell ◽

The Impact ◽

Related Mortality

Abstract Background Mycobacterium avium–intracelllulare complex (MAC) prophylaxis is recommended for patients with CD4 counts of < 50 cells/mm3. With the significant decrease in incidence of disseminated MAC infection and the effective immune recovery due to the availability of combination antiretroviral therapy (ART), the benefits of giving MAC prophylaxis were investigated. This study examined the impact of macrolide prophylaxis on AIDS-defining conditions and HIV-associated mortality in a cohort of HIV-infected patients on ART. Methods TREAT Asia HIV Observational Database (TAHOD) patients aged ≥18 years with a CD4 count < 50 cells/mm3 at ART initiation were included. The effect of macrolide prohylaxis on HIV-associated mortality or an AIDS event (as a combined outcome) and HIV-associated mortality alone were evaluated using competing risk regression. Sensitivity analysis was conducted to assess whether results were consistent in patients with a CD4 < 100 cells/mm3 at ART initiation. Results Of 1,345 eligible patients (78% male with median age at ART initiation of 34.8 years), 10.6% received macrolide prophylaxis. The rates of the combined outcome and HIV-associated mortality per 100 patient years were 7.35 [95% confidence interval (CI): 6.04–8.95] and 3.14 (95% CI: 2.35–4.19), respectively. After adjusting for possible confounders, macrolide use was associated with a significantly decreased risk of HIV-associated mortality (HR 0.10, 95% CI: 0.01–0.80, P = 0.031) but not the combined outcome (HR 0.86, 95% CI: 0.32–2.229, P = 0.764). Sensitivity analyses showed that, among patients with a CD4 < 100 cells/ mm3 at ART initiation, these results were consistent. Conclusion Macrolide prophylaxis is associated with significantly improved survival among Asian HIV-infected patients with very low CD4 cell counts. The benefits of giving macrolide prophylaxis remain despite the availability of effective ART. Disclosures All authors: No reported disclosures.

Download Full-text

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Blood ◽

10.1182/blood-2014-05-579136 ◽

2014 ◽

Vol 124 (16) ◽

pp. 2507-2513 ◽

Cited By ~ 311

Author(s):

Ayalew Tefferi ◽

Paola Guglielmelli ◽

Dirk R. Larson ◽

Christy Finke ◽

Emnet A. Wassie ◽

...

Keyword(s):

Polycythemia Vera ◽

Essential Thrombocythemia ◽

Blast Transformation ◽

Term Survival ◽

Free Survival ◽

Long Term Survival ◽

Mutational Status ◽

Key Points

Key Points Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2/CALR/MPL mutational status is prognostically informative in PMF, regarding overall and leukemia-free survival.

Download Full-text

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Blood ◽

10.1182/blood-2015-06-649111 ◽

2015 ◽

Vol 126 (24) ◽

pp. 2578-2584 ◽

Cited By ~ 80

Author(s):

Gerhard Zugmaier ◽

Nicola Gökbuget ◽

Matthias Klinger ◽

Andreas Viardot ◽

Matthias Stelljes ◽

...

Keyword(s):

T Cell ◽

Cell Kinetics ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Term Survival ◽

Long Term Survival ◽

Disease Response ◽

Key Points ◽

Minimal Residual

Key Points Ten of 36 patients (28%) achieved an OS ≥30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.

Download Full-text